A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
Completed
Atridia Pty Ltd.
Phase 1
This is a multicenter, dose-escalation/expansion phase 1 trial to evaluate the safety,
tolerability and efficacy of SHR3680 with or without SHR3162 given orally to subjects with
metastatic castration-resistant prostate cancer (mCRPC).
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors
Completed
Atridia Pty Ltd.
Phase 1
This is an open-label, multicenter, non-randomized, dose-escalation phase 1 trial to evaluate
the safety and tolerability of SHR3162 in participants with advanced solid tumors.
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
Unknown status
Beijing Cancer Hospital
Phase 1
Fluzoparib is an oral potent, selective poly-ADP ribose polymerase-1 (PARP-1) and PARP-2
inhibitor; Apatinib is an oral selective vascular endothelial growth factor receptor (VEGFR)
inhibitor. This open-label, dose finding phase I trial studies the tolerability and the best
dose of fluzoparib in combination with apatinib and to see how well these two drugs work
together in the treatment of patients with recurrent ovarian cancer or triple negative breast
cancer. The safety and efficacy of fluzoparib in combination with apatinib will be explored.
Both dose escalation and dose expansion parts are included in this study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
